公开(公告)号：US20240092933A1

公开(公告)日：2024-03-21

申请号：US18511308

申请日：2023-11-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/30 ,  C07K16/2809 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

公开(公告)号：US20220185888A1

公开(公告)日：2022-06-16

申请号：US17686358

申请日：2022-03-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Martin HOFMANN ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER

IPC: C07K16/28 ,  C07K16/46 ,  C07K16/10 ,  C07K16/30

Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated viral peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

公开(公告)号：US20220098270A1

公开(公告)日：2022-03-31

申请号：US17553017

申请日：2021-12-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER ,  Mathias FERBER

IPC: C07K14/725 ,  C07K14/47 ,  A61K35/17 ,  C12N5/0783 ,  C12N5/10 ,  A61K35/12

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20210048442A1

公开(公告)日：2021-02-18

申请号：US16990701

申请日：2020-08-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Meike HUTT ,  Toni WEINSCHENK ,  Sebastian BUNK ,  Oliver SCHOOR ,  Linus BACKERT ,  Martin HOFMANN ,  Jens FRITSCHE ,  Felix UNVERDORBEN ,  Gisela SCHIMMACK ,  Florian SALOPIATA

IPC: G01N33/68

Abstract: The present invention relates to a method for the characterization of peptide:MHC binding polypeptides, e.g. by mass spectrometry and an analysis of the recognized peptide space, i.e. in order to identify peptides that can be bound in the context of their presentation by MHC, and those who cannot be bound.

公开(公告)号：US20200254106A1

公开(公告)日：2020-08-13

申请号：US16826946

申请日：2020-03-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER ,  Claudia WAGNER

IPC: A61K47/55 ,  A61K47/64 ,  A61P35/00 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C12N5/00 ,  C12N15/85

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20190016801A1

公开(公告)日：2019-01-17

申请号：US16035403

申请日：2018-07-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Martin HOFMANN ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER

IPC: C07K16/28 ,  C07K16/10 ,  C07K16/30

Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

公开(公告)号：US20180135039A1

公开(公告)日：2018-05-17

申请号：US15813879

申请日：2017-11-15

Applicant: immatics biotechnologies GmbH

Inventor： Sebastian BUNK ,  Dominik MAURER ,  Felix UNVERDORBEN

IPC: C12N13/00 ,  C12N15/10 ,  C12N15/87 ,  C07K14/725 ,  C12N1/16

Abstract: The present invention relates to improved yeast transformation of yeast cells and yeast cell libraries transformed thereby. More specifically, the present invention relates to the transformation of yeast by electroporation.

公开(公告)号：US20250122302A1

公开(公告)日：2025-04-17

申请号：US18989486

申请日：2024-12-20

Applicant: Immatics Biotechnologies GmbH

Inventor： Sara YOUSEF ,  Fabian BRUNK ,  Andreas MORITZ ,  Sebastian BUNK ,  Claudia WAGNER ,  Dominik MAURER ,  Felix UNVERDORBEN

IPC: C07K16/30 ,  C07K14/725 ,  G01N33/574

Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.

公开(公告)号：US20250034227A1

公开(公告)日：2025-01-30

申请号：US18785378

申请日：2024-07-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Felix UNVERDORBEN ,  Sebastian BUNK ,  Martin HOFMANN ,  Meike HUTT ,  Timo MANZ ,  Nadine ASCHMONEIT ,  Maike JAWORSKI ,  Lena SCHMOHL ,  Claudia WAGNER ,  Dominik MAURER ,  Heiko SCHUSTER ,  Nora TREIBER

IPC: C07K14/725 ,  A61K38/00 ,  A61P35/00

Abstract: The present invention relates to antigen binding proteins that specifically bind to a tumor expressed melanoma-associated antigen (MAGE) B2 antigenic peptide in a complex with MHC. The antigen binding proteins are provided for use in the treatment of MAGEB2-expressing cancers. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins.

公开(公告)号：US20240279308A1

公开(公告)日：2024-08-22

申请号：US18581947

申请日：2024-02-20

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Dominik MAURER ,  Sebastian BUNK ,  Leonie ALTEN

IPC: C07K14/725 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  A61K38/00 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10

CPC classification number: C07K14/7051 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10 ,  A61K38/00

Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tmor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.